1. Home
  2. NVAX vs SCL Comparison

NVAX vs SCL Comparison

Compare NVAX & SCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • SCL
  • Stock Information
  • Founded
  • NVAX 1987
  • SCL 1932
  • Country
  • NVAX United States
  • SCL United States
  • Employees
  • NVAX N/A
  • SCL N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • SCL Package Goods/Cosmetics
  • Sector
  • NVAX Health Care
  • SCL Consumer Discretionary
  • Exchange
  • NVAX Nasdaq
  • SCL Nasdaq
  • Market Cap
  • NVAX 1.3B
  • SCL 1.2B
  • IPO Year
  • NVAX 1995
  • SCL N/A
  • Fundamental
  • Price
  • NVAX $6.80
  • SCL $59.25
  • Analyst Decision
  • NVAX Buy
  • SCL
  • Analyst Count
  • NVAX 5
  • SCL 0
  • Target Price
  • NVAX $16.60
  • SCL N/A
  • AVG Volume (30 Days)
  • NVAX 5.2M
  • SCL 93.2K
  • Earning Date
  • NVAX 08-07-2025
  • SCL 07-30-2025
  • Dividend Yield
  • NVAX N/A
  • SCL 2.60%
  • EPS Growth
  • NVAX N/A
  • SCL 47.62
  • EPS
  • NVAX 2.97
  • SCL 2.45
  • Revenue
  • NVAX $1,254,962,000.00
  • SCL $2,222,111,000.00
  • Revenue This Year
  • NVAX $56.85
  • SCL $8.56
  • Revenue Next Year
  • NVAX N/A
  • SCL $6.89
  • P/E Ratio
  • NVAX $2.29
  • SCL $24.19
  • Revenue Growth
  • NVAX 25.92
  • SCL N/A
  • 52 Week Low
  • NVAX $5.01
  • SCL $44.23
  • 52 Week High
  • NVAX $17.81
  • SCL $94.77
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.68
  • SCL 66.35
  • Support Level
  • NVAX $6.23
  • SCL $54.28
  • Resistance Level
  • NVAX $6.90
  • SCL $56.24
  • Average True Range (ATR)
  • NVAX 0.30
  • SCL 1.46
  • MACD
  • NVAX 0.01
  • SCL 0.41
  • Stochastic Oscillator
  • NVAX 67.00
  • SCL 94.74

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About SCL Stepan Company

Stepan Co manufactures and sells a variety of chemicals and chemical-based products. The company organizes itself into three segments based on product type. The surfactants segment, which generates the majority of revenue, sells cleaning agents used in detergents, shampoos, body wash, fabric softeners, toothpastes, and other personal-care products. The polymers segment sells polyurethane used to manufacture rigid foam for thermal insulation, as well as phthalic anhydride used to make plastic components for the construction, automotive, and boating industries. The specialty products segment sells chemicals used in food and flavoring. The majority of Stepan's revenue comes from the United States, followed by France, Poland, the United Kingdom, Brazil, Mexico, and other countries.

Share on Social Networks: